Objective : To describe and contrast to what has been described in other regions the effect of SGLT2 inhibitors in new users in an private specialized outpatient Endocrinology clinic in Tegucigalpa, Honduras during the period from March 2015 to May 2018.
Methods : This is a descriptive ,retrospective study in which 95 type 2 diabetes patients who were new users of SGLT2 inhibitors were evaluated; data was collected from clinical files inn patients who had received the treatment for at least 6 months and an SPSS database was created ; frequency distribution data was analyzed as were cross tabulations.
Results : Most 58.9% (n=56) were female and 41.1% (n=39) were male and 80% were in a median age ranging from 30-60 years old. Most 71.4 % (n=71) have less than 10 years of known diabetes. Patients had been on the drug a median of 14 months; median A1c before treatment was 7.23%,with an average delta of -0.48% after use of the drug. The median of weight before use was 86.5kg with a delta of +0.45 Kg, with a range from +10.4 kg to -13.1 kg. Urogenital complications were found in 9.5% of treated patients with 8 cases of vulvovaginitis and 2 cases of balanitis. No DKA, hypoglicemia, Acute renal failure, UTI or dehydration were found.
Discussion : The change in A1c was as expected 0.4-1.1% near the lower limit specially since most patients were already near glycemic objectives; the failure to loose the weight that is usually seen with this drugs is probable due too the sample size and it’s heterogeneous nature.
Conclusion : This small study showed that it is safe to use this new class of drugs in this population even in those who have good glycemic control and that bigger more complete real world studies are needed for this class in our local population.
Maria Alejandra Ramos Guifarro– Chief of Endocrinology, Hospital Escuela Universitario, Tegucigalpa, Francisco Morazan, Honduras
Irma De Vicente– Internal Medicine, Hospital Escuela Universitario
Scarleth Betzabel Rodas– Medical Student, Universidad Nacional autonoma de Honduras
Daniel Andrés Guifarro Rivera– Medical Student, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Francisco Morazan, Honduras
Chief of Endocrinology
Hospital Escuela Universitario
Tegucigalpa, Francisco Morazan, Honduras
Chief of Endocrinology Hospital Escuela
Universidad Nacional autonoma de Honduras